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Abstract
Cancer patients undergoing treatment with systemic cancer chemotherapy drugs often experience debilitating fatigue
similar to sickness behavior, a normal response to infection or tissue damage caused by the production of the inflammatory
cytokines IL-1b, TNF-a, and IL-6. The p38 mitogen activated protein kinase (p38 MAPK) plays a central role in the production
of these cytokines and consequently the development of sickness behavior. Targeted inhibitors of p38 MAPK can reduce
systemic inflammatory cytokine production and the development of sickness behavior. Several systemic cancer
chemotherapy drugs have been shown to stimulate inflammatory cytokine production, yet whether this response is
related to a common ability to activate p38 MAPK is not known and is the focus of this study. This understanding may
present the possibility of using p38 MAPK inhibitors to reduce chemotherapy-induced inflammatory cytokine production
and consequently treatment-related fatigue. One caveat of this approach is a potential reduction in chemotherapeutic
efficacy as some believe that p38 MAPK activity is required for chemotherapy-induced cytotoxicity of tumor cells. The
purpose of this study was to demonstrate proof of principal that p38 MAPK inhibition can block chemotherapy- induced
inflammatory cytokine production without inhibiting drug-induced cytotoxicity using murine peritoneal macrophages and
Lewis Lung Carcinoma (LLC1) cells as model cell systems. Using these cells we assessed the requirement of etoposide,
doxorubicin, 5-flourouracil, and docetaxel for p38 MAPK in inflammatory cytokine production and cytotoxicity. Study
findings demonstrate that clinically relevant doses of etoposide, doxorubicin, and 5-FU activated p38 MAPK in both
macrophages and LLC1 cells. In contrast, docetaxel failed to activate p38 MAPK in either cell type. Activation of p38 MAPK
mediated the drug’s effects on inflammatory cytokine production in macrophages but not LLC1 cytotoxicity and this was
confirmed with inhibitor studies.
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Introduction
Sickness behavior describes a cluster of symptoms including
fatigue, loss of appetite, and disturbed sleep that is initiated by
increased production of the inflammatory cytokines IL-1b, TNF-
a, and IL-6. Studies in humans and in animal models have
demonstrated the role that these cytokines play in the development
of sickness behavior [1,2,3,4,5,6]. The p38 mitogen activated
protein kinase (p38 MAPK) plays a central role in the
inflammatory cytokine response to immune challenge and
consequently the development of sickness behavior. Specifically,
in a recent study a human model of systemic inflammation was
used to determine the role of p38 MAPK activity in the cytokine-
induced sickness behavior response to low dose (4 ng/kg) bacterial
lipopolysaccharide (LPS) [7]. In this model p38 MAPK activity in
peripheral blood mononuclear cells (PBMC) peaked within 1-hour
of LPS injection, followed by an increase in plasma levels of TNF-
a and IL-6 which peaked at 3–4 hours post injection and returned
to baseline soon thereafter [7]. The rise in plasma levels of these
cytokines coincide with the symptoms of sickness behavior [2,7]. A
similar relationship between p38 MAPK activity and cytokine
production was observed in vitro using LPS-stimulated PMBCs. To
assess the role of p38 MAPK in LPS-induced cytokine production
and the induction of sickness behavior, participants were treated
with the p38 MAPK inhibitor BIRB796 (Boeringher Ingelheim)
prior to LPS injection [7]. BIRB796 pretreatment blocked p38
MAPK activation in PBMC and the rise in plasma cytokine levels
in response to LPS injection [7]. Consequently LPS-induced
sickness behaviors were attenuated in the BIRB796 pre-treatment
group [7]. Similar findings have been obtained from in vivo animal
studies using a different p38 MAPK inhibitor, SB203580
(Calbiochem) which protected mice from endotoxic shock
following administration of a lethal dose of LPS [8].
Over the last decade, there has been much speculation that the
fatigue commonly experienced by cancer patients undergoing
systemic cytotoxic chemotherapy is the same as sickness behavior
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cytotoxic chemotherapy drugs to induce fatigue may be related in
part to their ability to induce inflammatory cytokine production
via activation of p38 MAPK in target cells. There are two lines of
evidence that support this idea. First, cytotoxic chemotherapy
drugs have been shown to activate p38 MAPK in several tumor
cell lines [10,11,12,13,14]. Importantly, in this context, p38
MAPK activity has been proposed to play a role in drug-induced
cytotoxicity although several studies do not support this [10].
Second, several studies have shown that commonly used cancer
chemotherapy drugs can stimulate the production of inflammatory
cytokines. Many of these prior studies focused on examining
changes in inflammatory cytokines following drug administration
in experimental animal models. In this context drug-induced
damage to susceptible tissues is likely a significant stimulus for
inflammatory cytokine production. We recently found that mice
administered etoposide displayed a rapid increase in blood levels
of IL-6 that peaked at 3–6 hours post-administration [15]. Similar
findings were observed with the alkylating agent cyclophospha-
mide [16]. Splenocytes collected from mice administered clinically
relevant doses of cytarabine, cisplatin, etoposide, or melphalan
display an increase in the synthesis of several cytokines, including
TNF-a [17]. Moreover, macrophages collected from peritoneal
exudates from doxorubicin treated mice displayed increased
tumoricidal activity compared to those from untreated mice due
most likely to increased production of TNF- a [18]. Finally,
cisplatin-induced nephrotoxicity is associated with increased
production of TNF- a [19,20,21]. In addition to these in vivo
studies, several in vitro studies have shown that cytotoxic
chemotherapies can directly stimulate an innate immune response
in target cells. Specifically, paclitaxel can induce inflammatory
cytokine production in murine macrophage cell lines and in
human PBMCs [22,23,24,25,26,27,28,29] which is most likely
related to its ability to mimic the action of bacterial lipopolysac-
charide (LPS) [24,25,26,29,30]. Although paclitaxel can also
activate p38 MAPK in these cells it is unclear whether its activity is
required for inflammatory cytokine production. Other studies
including our own have demonstrated that several other cytotoxic
cancer chemotherapy drugs can stimulate the production of
inflammatory cytokines in macrophages and monocytes in vitro.
For instance, we have demonstrated that etoposide can induce IL-
6 in murine macrophages in vitro [15]. Etoposide has also been
shown to induce TNF-a in human monocytes [31]. The active
metabolite of cyclophosphamide can induce IL-6 production by
murine peritoneal macrophages in vitro [16]. In addition, the
related alkylating agents cisplatin and carboplatin have also been
shown to induce IL-1b, TNF-a and IL-6 production in
human monocytes [32] and in murine macrophages
[32,33,34,35,36,37,38,39]. It is important to note that the
requirement for p38 MAPK in chemotherapy induced inflamma-
tory cytokine production was not examined in these studies. The
requirement for p38 MAPK in this cytokine response was recently
investigated by our group. We found that etoposide activated p38
MAPK in murine peritoneal macrophages in vitro, and induced the
production of IL-6 [15]. Blocking p38 MAPK activity with a
specific p38 MAPK inhibitor (ML3403; Calbiochem) blocked
etoposide-mediated induction of IL-6 production in these cells
[15]. Whether other chemotherapy drugs can induce inflamma-
tory cytokine production via p38 MAPK activation is not known.
Understanding whether this is the case may offer the possibility of
using p38 MAPK inhibitors to decrease inflammatory cytokine
production in vivo thereby ameliorating cancer treatment related
fatigue. However, one potential caveat to this approach is that p38
MAPK activity is considered by some to be essential for drug
induced cytotoxicity. Specifically, several studies employed specific
p38 MAPK inhibitors to block the chemotherapy-induced
activation of the p38 MAPK pathway. In the majority of these
studies, inhibition of p38 MAPK activity in chemotherapy treated
cancer cell lines was associated with a modest reduction in drug-
induced cytotoxicity [14]. However, an important limitation of
these studies is that they fail to establish a direct correlation
between the activation of p38 MAPK by cancer chemotherapy
drugs and drug-induced cytotoxicity.
The purpose of this study was to demonstrate proof of principal
that p38 MAPK inhibition can block cytotoxic chemotherapy-
induced inflammatory cytokine production without inhibiting
drug-induced cytotoxicity using murine peritoneal macrophages
and Lewis Lung Carcinoma (LLC1) cells as model cell systems.
Using these cells we assessed the requirement of etoposide,
doxorubicin, 5-flourouracil, and docetaxel for p38 MAPK in
inflammatory cytokine production and cytotoxicity. These drugs
were chosen because they are commonly used in the treatment of
cancer and represent different drug categories: epidodophyllotox-
ins (etoposide), anthracyclines (doxorubicin), anti-metabolites (5-
FU), and mitotic inhibitors (docetaxel). Study findings demonstrate
that clinically relevant doses of etoposide, doxorubicin, and 5-FU
activated p38 MAPK in both macrophages and LLC1 cells. In
contrast docetaxel at the dosage used failed to activate p38 MAPK
in either cell type. Activation of p38 MAPK mediated the drug’s
effects on inflammatory cytokine production in macrophages but
not LCC1 cell cytotoxicity and this was confirmed with inhibitor
studies.
Results
The induction of inflammatory cytokines by etoposide, 5-
FU, doxorubicin, and docetaxel in murine macrophages
in vitro is mediated by p38 MAPK
In our earlier study we showed that etoposide could activate p38
MAPK in murine macrophages [15]. To determine whether other
cytotoxic chemotherapeutic drugs from different drug classes share
a common ability to activate p38 MAPK in these cells, we
incubated macrophages with clinically relevant concentrations of
etoposide (50 mM), 5-fluorouracil (250 mM), doxorubicin (1 mM),
and docetaxel (5 mM). We found that similar to etoposide, 5-FU
and doxorubicin could also activate p38 MAPK, as evidenced by
an increase in phosphorylated p38 MAPK relative to total p38
MAPK in drug-treated versus carrier-treated cells (Figure 1A). In
contrast docetaxel failed to activate p38 MAPK at a dose of 5 mM
(Figure 1A) and this finding was observed even when cells were
treated with supraphysiological doses (100 mM) of the drug (Data
not shown). Consistent with a role for p38 MAPK activation in
inflammatory cytokine production we found that drug-induced
p38 MAPK activity was associated with increased production of
IL-1b, TNF-a, and IL-6. Specifically, etoposide, 5-FU, and
doxorubicin treatment led to a significant accumulation of IL-1b
and IL-6 mRNAs (Figure 1B). TNF-a mRNA levels also increased
in etoposide and 5-FU-treated cells but decreased in those treated
with doxorubicin (Figure 1B). A similar decline in TNF-a mRNA
was observed in cells treated with docetaxel (Figure 1B). In
general, increased levels of cytokine mRNAs were associated with
an increase in the corresponding cytokine in the culture medium
(Figure 1C). The exceptions were IL-1b in 5-FU-treated cells and
all three cytokines in doxorubicin-treated cells. In the case of
doxorubicin we found that prolonged exposure of cells to
doxorubicin (.24 hr) lead to significant cell death which most
likely explained why levels of IL-1b, TNF-a and IL-6 did not
accumulate above the threshold of detection by immunoassay in
Anticancer Drugs & Cytokines
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tion of doxorubicin to 10 mM levels of cytokines were detectable
and reflected the levels of cytokine mRNA (data not shown and
Figure 2).
To determine whether p38 MAPK activity was required for
chemotherapy-induced inflammatory cytokine production we pre-
treated cells with the p38 MAPK inhibitor prior to the addition of
50 mM etoposide, 250 mM 5-FU, or 10 mM doxorubicin. Pre-
treatment with the p38 MAPK inhibitor was sufficient in blocking
p38 MAPK signaling as evidenced by a decrease in levels of
phosphorylated- MAPKAPK-2, a downstream target of activated
p38 MAPK (Figure 2A).
Suppression of p38 MAPK activity in etoposide, 5-FU, and
doxorubicin-treated cells blocked the accumulation of one or more
of the cytokines (Figure 2B & C). DMSO, the p38 MAPK inhibitor
carrier, appeared to decrease the magnitude of the IL-1b, TNF-a,
and IL-6 response to etoposide, 5-FU, and doxorubicin treatment
(Compare Figures 1B & C and Figure 2 B & C). Nonetheless, these
experiments demonstrate that the induction of inflammatory
cytokines by etoposide, 5-FU, and doxorubicin in murine
macrophages is p38 MAPK dependent.
The cytotoxic effects of etoposide, 5-fluorouracil,
doxorubicin, and docetaxel are not associated with p38
MAPK activation in LLC11 cells
Previous studies have implicated p38 MAPK activation in
chemotherapy-induced cytotoxicity. One limitation of these earlier
studies is that they used supraphysiological doses of drug and failed
to establish a direct correlation between the activation of p38
MAPK and drug-induced cytotoxicity. To address these limita-
tions we performed proliferation assays with increasing concen-
trations of each drug. Etoposide, 5-FU, doxocrubicin, and
docetaxel were able to inhibit the proliferation of LLC11, although
we did not observe a direct relationship between p38 MAPK
activation and cytotoxicity (Figure 3A). Indeed, docetaxel
decreased p38 MAPK activity in LLC1 cells. These findings
suggest that p38 MAPK is not a pre-requisite for chemotherapy-
induced cytotoxicity in LLC1 cells. Nonetheless at higher
concentrations of etoposide (100 mM), doxorubicin (10 mM), and
5-FU (100 mM) p38 MAPK was evident (Figure 3 A). Therefore to
confirm that p38 MAPK activation was not required for drug-
induced cytotoxicity we performed proliferation assays with these
drug concentrations in the presence or absence of the p38 MAPK
inhibitor. Blockade of p38 MAPK activity did not inhibit the anti-
proliferative effects of etoposide, 5-FU and doxorubicin (Figure 3
B). In fact, p38 blockade enhanced the anti-proliferative effects of
5-FU (Figure 3B). Taken together our data show that some cancer
chemotherapy drugs can activate the p38 MAPK pathway, but the
biological consequences of its activation in LLC1 remain unclear.
Discussion
It has long been speculated that the fatigue that occurs in cancer
patients during treatment with systemic cytotoxic chemotherapy
drugs may be caused by an increase in production of inflammatory
cytokines and thereby could be similar to sickness behavior.
Several studies demonstrating the induction of inflammatory
cytokines in response to cytotoxic chemotherapies in immunolog-
ically-derived cells in vitro and in experimental animals support this
idea. The p38 MAPK plays an important role in the production of
inflammatory cytokines and the development of sickness behavior
and activation of p38 MAPK has been observed in several tumor
cell lines treated with a variety of cytotoxic chemotherapies.
Figure 1. The induction of inflammatory cytokines by etoposide, 5-FU, doxorubicin, and docetaxel in murine macrophages in vitro
is mediated by p38 MAPK. A) Levels of phosphorylated p38 MAPK and total p38 MAPK in murine peritoneal macrophages incubated with
etoposide, 5-FU, doxorubicin, and docetaxel were assessed by immunoblotting. B) Relative levels of IL-1b, TNF-a and IL-6 mRNA in etoposide, 5-FU,
doxorubicin, and docetaxel-treated macrophages assessed by QRT-PCR. Fold increase in expression of each cytokine mRNA in drug-treated cells
relative to carrier-treated cells is shown. C) Levels of IL-1b, TNF-a and IL-6 in the culture medium of macrophages incubated with etoposide, 5-FU,
doxorubicin, and docetaxel.
doi:10.1371/journal.pone.0002355.g001
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cytokine response to immune challenge and decrease sickness
behavior and several pharmaceutical companies are currently
investing in the development of p38 MAPK inhibitors for the
treatment of inflammatory diseases [40,41,42]. Understanding
whether p38 MAPK plays a role in the induction of inflammatory
cytokines in response to cytotoxic chemotherapies, could support
the use of p38 MAPK inhibitors in the management of cancer
treatment-related fatigue. However, there have been few studies
that have assessed whether the inflammatory cytokine response to
chemotherapy occurs in a p38 MAPK-dependent manner. The
data presented herein show a direct role for p38 MAPK in the
induction of inflammatory cytokines by etoposide, 5-FU, and
doxorubicin using murine macrophages as a model system.
Not all of the chemotherapy drugs tested in this study were able
to activate p38 MAPK; docetaxel failed to activate p38 MAPK in
either macrophages or LLC1 cells even at supraphysiological
concentrations. These findings are consistent with those of a prior
study in which 100 mM docetaxel failed to induce inflammatory
cytokines in the murine macrophage cell line RAW 246.7 and in
peritoneal macrophages collected from LPS-responsive CH3/OuJ
mice [25]. In these earlier studies the ability of docetaxel to
activate p38 MAPK was not investigated. Our findings suggest
that its failure to induce inflammatory cytokine production in
immune cells is most likely due to its failure to activate p38
MAPK. In light of this finding and for our hypothesis to be correct
we would expect that docetaxel will not cause sickness behavior
(i.e. fatigue) because it does not activate p38 MAPK and
consequently fails to induce inflammatory cytokine production in
target cells. Unfortunately there are no studies in cancer patients
that have focused on determining whether certain drug types are
associated with fatigue more than others. Indeed, testing this
hypothesis in the clinical setting may be difficult as docetaxel is
often administered in combination with other chemotherapeutics
making the contribution of this drug alone to fatigue burden
impossible to determine. An alternative approach would be to
examine the inflammatory cytokine response to docetaxel
administration alone in a mouse model of sickness behavior. We
used a similar approach recently to determine whether etoposide
could induce inflammatory cytokine production and sickness
behaviors when administered to mice [15]. Using this model we
would expect that a clinically relevant dose of docetaxel would not
induce inflammatory cytokine production or sickness behavior.
These experiments are clearly warranted and are currently
underway.
Of interest was the finding that doxorubicin and docetaxel
decreased production of TNF-a in macrophages. Our findings are
consistent with previous studies in which doxorubicin failed to
induce the production of TNF-a in peritoneal exudates cells from
doxorubicin treated mice [37]. Inhibition of p38 MAPK activity in
doxorubicin-treated cells failed to further decrease TNF-a
production by these cells. Taken together these findings suggest
that the ability of doxorubicin and docetaxel to decrease TNF-a
level in macrophages is p38 MAPK independent. The fact that
decreased TNF-a levels can occur in the context of increased
production of IL-1b and IL-6 suggests that depending upon the
stimulus, IL-1b, TNF-a and IL-6 production by murine
macrophages are governed by distinct molecular events.
Why docetaxel fails to activate p38 MAPK may be related to its
ability to induce oxidative stress [43]. Indeed unlike docetaxel,
both etoposide and doxorubicin are known to be strong inducers
of reactive oxygen species (ROS). In the case of doxorubicin, ROS
induction is believed to mediate the cardiotoxic effects of this drug
[44]. Although, 5-FU known to be a weak inducer of ROS, like
docetaxel, it still induced p38 MAPK in both macrophages and
LLC1 in the present study. Our experiments using DMSO, the
Figure 2. The effect of p38 MAPK blockade on etoposide, 5-FU, and doxorubicin mediated induction of inflammatory cytokine
production in murine macrophages. (A) Inhibition of p38 MAPK leads to a reduction in MAPKAPK-2 phosphorylation , a downstream target of
p38 MAPK. (B) The effect of pre-treatment with the p38 MAPK inhibitor on IL-1b, TNF-a and IL-6 mRNA levels. Fold increase in expression of each
cytokine mRNA in drug treated cells and in cells treated with drug plus inhibitor relative to carrier treated cells is shown. (C) Levels of IL-1b, TNF-a and
IL-6 in the culture supernatant of drug treated cells. A significant decrease (p,0.05) in cytokine level in cells treated with drug plus p38 MAPK
inhibitor relative to cells treated with drug alone is denoted by an asterisk.
doi:10.1371/journal.pone.0002355.g002
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in part in drug-induced p38 MAPK activation. Specifically
DMSO appeared to decrease the magnitude of the IL-1b, TNF-
a, and IL-6 response to etoposide, 5-FU, and doxorubicin
treatment (Compare Figures 1B & C and Figure 2 B & C).
Clearly additional experiments are needed to understand the
relationship between drug-induced oxidative stress, and p38
MAPK activation in these cell types. Understanding whether
drug-induced oxidative stress underlies p38 MAPK activation and
inflammatory cytokine production in this context may provide an
additional strategy to ameliorate fatigue in cancer patients
undergoing treatment with certain cancer chemotherapeutics.
However one important consideration is the effect of p38 MAPK
blockade on drug-induced cytotoxicity. For several tumor cell
lines, in vitro activation of p38 MAPK following exposure to
mechanistically different chemotherapeutic agents has been
established [45,46,47]. Our data further support the ability of
some cytotoxic chemotherapies to activate p38 MAPK in LLC1
cells. However, our findings fail to support the idea that p38
MAPK activity is essential for drug-induced cytotoxicity. First we
did not examine a direct correlation between drug-induced
inhibition of LLC1 cell proliferation and p38 MAPK activation.
Although high concentrations of etoposide, 5-FU and doxorubicin
did activate p38 MAPK, further experiments with a p38 MAPK
inhibitor did not support a role for this enzyme in drug induced
cell killing. In the case of 5-FU, pre-treatment of cells with the p38
MAPK inhibitor enhanced the cytotoxic effects of this drug. Boldt
et al., also demonstrated a similar enhancement of the cytotoxic
effects of etoposide in several tumor cell lines by the p38 MAPK
inhibitor SB203580 [47]. Our data support the idea that p38
MAPK blockade may selectively diminish cytotoxic chemotherapy
drug-induced inflammatory cytokine production without decreas-
ing their anti-tumorigenic activity. Clearly additional studies are
warranted to assess the consequence of p38 MAPK blockade on
tumor growth and progression and treatment related sickness
behaviors in in vivo studies. While these experiments are currently
underway there are other studies that suggest the feasibility of this
approach. For instance, p38 MAPK has been shown to play an
Figure 3. The cytotoxic effects of etoposide, 5-fluorouracil, doxorubicin, and docetaxel are not associated with p38 MAPK
activation in LLC11 cells. A) The effect of increasing concentrations of etoposide, 5-FU, doxorubicin or docetaxel on p38 MAPK activation and
proliferation were assessed by immunoblotting and MTS assay respectively. B) The effect of p38 MAPK blockade on drug-induced cytotoxicity in LLC1
cells treated with etoposide, 5-FU or doxorubicin. Note that the addition of the p38 MAPK inhibitor appeared to enhance the cytotoxic effects of 5-FU
on LLC1 cells (see *).
doi:10.1371/journal.pone.0002355.g003
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likely through its ability to induce the production of TNF-a [19].
Pre-treatment of mice with the p38 MAPK inhibitor SB203580
significantly reduced cisplatin-induced nephrotoxicity [19]. It is
important to note that the effects of p38 MAPK inhibition on the
anti-tumor effects of cisplatin were not examined. However, a
similar study using an inhibitor of oxidative stress decreased
cisplatin-induced cytotoxicity while having no effect on tumor
growth [48]. Additional studies in this field may lead to new
treatment strategies aimed at reducing fatigue in cancer patients
undergoing systemic chemotherapy.
Materials and Methods
Reagents
Etoposide (20 mg/ml) solution was purchased from Novation
(Irving, TX, USA). Etoposide carrier (2 mg/ml citric acid, 30 mg/
ml benzyl alcohol, 80 mg/ml Tween-80, 650 mg/ml polyethylene
glycol 400, and 30.5% (v/v) ethanol) was used as an experimental
control. Doxorubicin-HCL was purchased as a lyophilized 10 mg
tablet from Bedford Labs (Bedford, OH, USA) and was dissolved
in sterile, deionized water to attain a stock solution of 1 mg/ml,
stored at 4uC. 5-FU was purchased as a 50 mg/ml solution from
American Pharmaceutical Partners (Schaumburg, IL, USA).
Sterile, deionized water served as a carrier control for doxorubicin
and 5-FU in experiments. Docetaxel powder was purchased from
Sigma Aldrich, Inc. (Dallas, TX, USA) and stored as a 25 mg/ml
solution in dimethylsulfoxide (DMSO) at 4uC. ML3403 (p38
MAPK Inhibitor III) was purchased from CalBiochem (San
Diego, CA, USA) and was prepared as a 10 mM stock solution in
DMSO. RPMI 1640 cell culture media was purchased from
Gibco (Grand Island, NY, USA). Fetal bovine serum (FBS) was
purchased from Atlanta Biologicals (Lawrenceville, GA, USA) and
was heat-inactivated by 30 min incubation at 56uC in a water
bath, followed by 30 min in an ice bath, prior to use in cell culture.
Brewer thioglycolate broth was obtained from Sigma-Aldrich, Inc.
and was prepared as an 4% (w/v) aqueous solution, aged in the
dark for at least one month prior to use.
Mice
Female 8-week-old C57BL/6 mice purchased from Jackson
Laboratories (Bar Harbor, ME) were housed five to a cage in
pathogen-free rooms (12-hour light-dark cycle) and had ad lib
access to food and water. At the time of sacrifice, mice were
terminally sedated using isofluorane according to protocols
established at OHSU Department of Comparative Medicine.
Murine Macrophage Harvest, Culture, and Drug
Treatment
Mice were administered 1 cc of sterile and aged 4% Brewer
thioglycolate broth by intraperitoneal (IP) injection. Thioglycolate-
elicited macrophages were harvested 3 days later by IP lavage with
10 cc sterile, room temperature Dulbecco’s phosphate buffered
saline (DPBS). Cells were seeded at 4610
6 viable cells per 6 cm
dish in 3 mL RPMI culture media containing 2% heat-inactivated
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (RPMI-
2). After 24-hours of incubation at 37uC/5% CO2, non-adherent
cells were washed from the wells with DPBS and etoposide,
doxorubicin, docetaxel or 5-fluorouracil was added to select wells
to final concentrations of 50 mM, 1 mMo r1 0mM, 5 mM and
250 mM, respectively, in final volumes of 1.5 ml of culture
medium. The drug concentrations used reflect peak plasma
concentrations observed during infusion in cancer patients
[49,50,51,52]. Separate wells were also incubated with drug
carrier alone. Each cell treatment was set up in duplicate, for
harvest at 6 & 48 hrs. In p38 MAPK inhibitor studies
macrophages were pretreated at 37uC/5% CO2 for 1 hour with
1.4 ml RPMI-2 containing 0.1% DMSO or 1.4 ml of RPMI-2
containing 10 mM ML3403. Following one hour of pretreatment,
50 mM etoposide, 250 mM 5-fluorouracil, or 10 mM doxorubicin,
were added to select wells, in final volumes of 1.5 ml. The drug
concentrations used reflect peak plasma concentrations observed
during infusion in cancer patients [49,50,51,52]. Separate wells
were also incubated with drug carrier alone. Each cell treatment
was set up in duplicate, for harvest at 6 & 48 hrs. After 6 & 48 hrs
incubation at 37uC/5% CO2, cell culture media was harvested
and centrifuged at maximum speed in a micro centrifuge for 3 min
to remove any cells. Residual culture media was removed from
cells by vacuum, and macrophage monolayers were disrupted
using 500 ml buffer RLT (Qiagen, Valencia, CA, USA) containing
10 ml b-mercaptoethanol per ml with the aid of sterile cell lifters.
Lysates were homogenized on QiaShredder columns (Qiagen,
Valencia, CA, USA) according to manufacturer protocol. Cell
lysates and cell-free culture media were stored at 270uC until use.
Each experiment was repeated in at least triplicate for all drug
combinations and time points.
Macrophage RNA and Protein Extraction
Total cellular RNA and protein were extracted concurrently
from macrophage lysates in buffer RLT using a method described
previously [53]. Briefly, RNA was extracted from cell lysates on
RNeasy Mini Spin Columns (Qiagen, Valencia, CA, USA)
according to the manufacturer’s protocol for animal cells. The
optional, on-column RNase-free DNase treatment was included to
remove any contaminating genomic DNA. Column effluent was
saved, pooled for each sample, and stored at ,220uC for 24–
48 hrs to allow protein precipitation. Precipitated protein was
collected by centrifugation at .10,000 g and 4uC, washed 36in
220uC 100% ethanol, dried at room temperature, and then
dissolved/denatured in SDS-PAGE loading buffer prior to western
blot analysis. RNA was used for qRT-PCR measurements of
relative IL-1b, TNF-a, and IL-6 mRNA levels.
Bead-based Immunoflourescence Assay
Levels of IL-1b, TNF-a, and IL-6 in macrophage culture media
were measured in duplicate in 3 separate assays using a bead-
based immunoflourescence assay (Luminex Inc., Austin, TX,
USA). Multiple cytokine analysis kits (LINCOplex kits) were
obtained from Linco Research Inc. (St. Charles, MO, USA) and
assays were performed according to the protocol supplied by the
manufacturer. Data were collected and analyzed using the
Luminex-100 system Version IS (Luminex, Austin, TX, USA). A
four or five-parameter regression formula was used to calculate the
sample concentrations from the standard curves.
Lewis Lung Cancer Cell Culture, Drug Treatment &
Proliferation Assays.
Lewis Lung Carcinoma 1 (LLC1) cells were previously derived
from a spontaneous, epidermoid lung carcinoma isolated from a
C57 Black/6 mouse [54], and were purchased from the American
Type Culture Collection (Atlanta, GA, USA). LLC1 cells were
cultured in DMEM supplemented with 10% FBS, 100-U/ml
penicillin, and 100 mg/ml streptomycin at 37uC in a humidified
incubator supplied to 5% of the atmosphere with CO2.T o
determine whether etoposide, 5-FU doxorubicin and docetaxel
could activate p38 MAPK, cells were plated onto 100 mm tissue
culture dishes and incubated with increasing concentrations of
Anticancer Drugs & Cytokines
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protein lysates prepared for immunoblotting. For proliferation
assays cells were plated at 4610
3 cells per well in 100 ml on 96-
well plates. Following incubation at 37uC5 %C O 2 overnight,
etoposide, 5-FU, doxorubicin, and docetaxel were added to the
cells at concentrations described in Figure 3. At 0, 24, and 48 h
post-addition of chemotherapeutic, cell viabilities in cultures were
determined by addition of 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell
proliferation reagent, incubated for 3 h at 37uC and 5% CO2, and
subsequently read at an absorbance at 490 nm. Seven wells of
culture were allotted for each drug concentration for each time
point. To evaluate the effect of p38 MAPK inhibition on the
ability of 50 mM etoposide, 100 mM 5-FU, and 10 mM doxoru-
bicin to inhibit LLC1 cell proliferation, cells were plated as
described above and then pre-treated with ML3403 at 10 mMo r
with DMSO carrier for 1 h at 37uC and 5% CO2. The final
concentration of DMSO in each culture was 0.1% (v/v). Following
p38 MAPK inhibitor pre-treatment, chemotherapeutic drugs were
added, followed by continued incubation at 37uC and 5% CO2.A t
0, 24, and 48 h post-addition of chemotherapeutic MTS assays
were performed as described above. All assays were performed in
triplicate.
Immunoblotting
Protein lysates from macrophages or LLC1 cells were resolved
by 4–15% gradient SDS-PAGE followed by transfer to poly-
vinylidene fluoride (PVDF) membranes. PVDF membranes were
blocked in a solution of 5% (w/v) bovine serum albumin, 10 mM
tris-HCL (pH8.0), 150 mM NaCl, 0.05% (v/v) Tween-20.
Immunoblotting was performed by gently rocking overnight at
4uC in blocking solution supplemented with one of the following
antibodies: rabbit anti-phospho-p38 MAPK (Thr180/Tyr182)
polyclonal antibody (1:1000, #9211, Cell Signaling Technology);
rabbit anti-p38 MAPKa polyclonal antibody (1:1000, #9218, Cell
Signaling Technology); rabbit anti-phospho-MAPKAPK-2
(Thr334) monoclonal antibody (1:1000, #3007, Cell Signaling
Technology); rabbit anti-MAPKAPK-2 polyclonal antibody
(1:1000, #3042, Cell Signaling Technology). Primary antibody
binding was detected with goat anti-rabbit IgG-horseradish
peroxidase (HRP) conjugate (1:5000, W401B, Promega Corp.,
Fitchburg, WI) and visualized using enhanced chemiluminescence
(ECL; Pierce, Rockford, IL, USA). ECL was recorded and
quantified using a Lumi-Imager in conjunction with LumiAnalyst
software (Boehringer Mannheim, Roche Diagnostics, Indianapo-
lis, IN, USA).
Quantitative Real Time Polymerase Chain Reaction (qRT-
PCR) Analysis
Relative IL-1b, TNF-a, and IL-6 mRNA levels were quantified
and normalized to GAPDH gene expression using two-step qRT-
PCR. In the first step, purified RNA was quantified and first-strand
cDNA synthesis was performed on ,3 mgR N Ai na3 0ml reaction
using an Omniscript RT kit (Qiagen, Valencia, CA, USA). In the
second step, IL-1b,T N F - a, IL-6, and GAPDH transcription in each
sample was quantified in separate reactions on an Opticon2 DNA
Engine (MJResearch, Waltham, MA, USA) using target-specific
primers and a target-specific fluorescence resonance energy transfer
(FRET) probe (Biosource, Camarillo, CA, USA). Primer and FRET
probe sequences were as follows: IL-1b 59-CTGTCGGACCCA-
TATGAGC-39 (forward), 59-GCTCATGGAGAATATCACT-
TGTTG-39 (reverse), 59-FAM-AAGCTCTCCACCTCAATGGA-
CAGA-BHQ1-39 (FRET probe); TNF 59-AGACCCTCACACT-
CAGATCATG-39 (forward), 59-TCAGCCACTCCAGCTGCT-39
(reverse), 59-FAM-CCACGTCGTAGCAAACCACCA-BHQ1-39
(FRET probe); IL-6 59-GCCCACCAAGAACGATAGTC-39 (for-
ward), 59-GTGGTTGTCACCAGCATCAG-39 (reverse), 59-FAM-
CTGCAAGAGACTTCCATCCAGTTGC-BHQ1-39 (FRET
probe); GAPDH 59-CCTCAACTACATGGTCTACATGTTC-39
(forward), 59-GCTCCTGGAAGATGGTGATG-39 (reverse), 59-
FAM-CATTCTCGGCCTTGACTGTGCCGT-BHQ1-39 (FRET
probe). Each qRT-PCR target was measured with 5 replicate wells
for each sample (n=5). Each qRT-PCR experiment was performed
in at least three independent populations of macrophages.
Analysis
For qRT-PCR analysis of IL-1b, TNF-a and IL-6 mRNA,
cytokine DCT values were compared after normalizing by
subtraction of GAPDH CT values from the same sample.
Differences in IL-1b, TNF-a and IL-6 DCT values between
drug-treated and control cells were analyzed using a two-tailed t-
test at the 95% confidence interval. Fold expression of each
cytokine in drug treated relative to control cells was calculated
using the DD CT method. Differences between levels of IL-1b,
TNF-a and IL-6 protein in macrophage culture media by group
were analyzed using a two-tailed t-test at the 95% confidence
interval. All data are presented as the mean +/2 standard error of
the mean. P,0.05 was considered to be statistically significant and
is denoted by an asterisk.
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